Special Issue "Recent Advances in Therapeutic Cancer Vaccines"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 15 January 2023 | Viewed by 119

Special Issue Editors

Dr. Manisha Singh
E-Mail Website
Guest Editor
Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: oncolmmunology; cancer immunotherapy; inflammation and cancer; anti-cancer CAR-T cells; microbiology
Dr. Shweta Dubey
E-Mail Website
Guest Editor
Amity Institute of Virology and Immunology (AIVI), Amity University, Noida, India
Interests: adjuvants; cancer immunotherapy; cancer immunology; immunology

Special Issue Information

Dear Colleagues,

Cancer has always been one of the leading causes of death worldwide. The prevention and treatment of cancer are important means to reduce the incidence of tumors and prolong the lives of patients. In recent years, the results of tumor immunotherapy in basic research and clinical research have attracted much attention. Many vaccines for the treatment of cancer have achieved amazing effects when used alone or in combination with other traditional cancer treatment methods, indicating that they have great clinical application potential. With the elucidation of the underlying mechanisms of cancer immunomodulation, effective, controllable and durable cancer vaccines will play an important role in cancer treatment, prolonged survival and recurrence and cancer prevention.

This Special Issue encourages submissions related to the progress and development of cancer vaccine research and clinical application of cancer immunity, in order to explore the obstacles in cancer vaccine research and promote the efficacy of cancer vaccines. At the same time, it also aims to discuss the future development and prospects of therapeutic cancer vaccines.

Dr. Manisha Singh
Dr. Shweta Dubey
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer vaccine
  • immunotherapy
  • therapeutic vaccine

Published Papers

This special issue is now open for submission.
Back to TopTop